Search

Your search keyword '"Van Roosbroeck, Katrien"' showing total 144 results
Start Over Author "Van Roosbroeck, Katrien"
144 results on '"Van Roosbroeck, Katrien"'

1. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Author

Vitale, Candida, Falchi, Lorenzo, Hacken, Elisa ten, Gao, Hui, Shaim, Hila, Van Roosbroeck, Katrien, Calin, George, O'Brien, Susan, Faderl, Stefan, Wang, Xuemei, Wierda, William G, Rezvani, Katayoun, Reuben, James M, Burger, Jan A, Keating, Michael J, and Ferrajoli, Alessandra

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Emerging Infectious Diseases, Cancer, Infectious Diseases, Hematology, Clinical Research, Rare Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Disease-Free Survival, Female, Humans, Lenalidomide, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Recurrence, Local, Thalidomide, Treatment Outcome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeWe evaluated efficacy and tolerability of the combination of ofatumumab and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), and explored whether immune system characteristics could influence the response to treatment.Experimental designThirty-four patients were enrolled in this phase II study. Ofatumumab was administered at a dose of 300 mg on day 1, 1,000 mg on days 8, 15, and 22 during course 1, 1,000 mg on day 1 during courses 3-6, and once every other course during courses 7-24 (28-day courses). Oral lenalidomide (10 mg daily) was started on day 9 and continued for as long as a clinical benefit was observed.ResultsThe overall response rate was 71%. Eight patients (24%) achieved a complete remission (CR) or CR with incomplete recovery of blood counts, including 9% with minimal residual disease-negative CR. The median progression-free survival was 16 months, and the estimated 5-year survival was 53%. The most common treatment-related toxicity was neutropenia (grade >2 in 18% of the 574 patient courses). The most frequent infectious complications were pneumonia and neutropenic fever (24% and 9% of patients, respectively). We observed that patients who achieved a CR had at baseline higher numbers and a better preserved function of T cells and natural killer cells compared with non-responders.ConclusionsThe combination of ofatumumab and lenalidomide is a well-tolerated regimen that induces durable responses in the majority of patients with relapsed/refractory CLL. Our correlative data suggest a role of competent immune system in supporting the efficacy of this treatment. Clin Cancer Res; 22(10); 2359-67. ©2016 AACR.

Published
2016

2. Epstein–Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival

Author

Ferrajoli, Alessandra, Ivan, Cristina, Ciccone, Maria, Shimizu, Masayoshi, Kita, Yoshiaki, Ohtsuka, Masahisha, D'Abundo, Lucilla, Qiang, Jun, Lerner, Susan, Nouraee, Nazila, Rabe, Kari G, Rassenti, Laura Z, Van Roosbroeck, Katrien, Manning, John T, Yuan, Yuan, Zhang, Xinna, Shanafelt, Tait D, Wierda, William G, Sabbioni, Silvia, Tarrand, Jeffrey J, Estrov, Zeev, Radovich, Milan, Liang, Han, Negrini, Massimo, Kipps, Thomas J, Kay, Neil E, Keating, Michael, and Calin, George A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Lymphoma, Genetics, Rare Diseases, Clinical Research, Cancer, Biotechnology, Hematology, Aetiology, 2.1 Biological and endogenous factors, Infection, Disease-Free Survival, Epstein-Barr Virus Nuclear Antigens, Herpesvirus 4, Human, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, MicroRNAs, RNA, Viral, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Viral Matrix Proteins, Viral Proteins, beta 2-Microglobulin, miRNAs, Epstein-Barr Virus, Chronic lymphocytic leukemia, BHRF1-1, Overall survival, Epstein–Barr Virus, Clinical Sciences, Public Health and Health Services, Clinical sciences, Epidemiology
Abstract

Although numerous studies highlighted the role of Epstein-Barr Virus (EBV) in B-cell transformation, the involvement of EBV proteins or genome in the development of the most frequent adult leukemia, chronic lymphocytic leukemia (CLL), has not yet been defined. We hypothesized that EBV microRNAs contribute to progression of CLL and demonstrated the presence of EBV miRNAs in B-cells, in paraffin-embedded bone marrow biopsies and in the plasma of patients with CLL by using three different methods (small RNA-sequencing, quantitative reverse transcription PCR [q-RT-PCR] and miRNAs in situ hybridization [miRNA-ISH]). We found that EBV miRNA BHRF1-1 expression levels were significantly higher in the plasma of patients with CLL compared with healthy individuals (p

Published
2015

4. Supplemental Figure 1 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Tables 1,2,3,4 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Author

Vitale, Candida, primary, Falchi, Lorenzo, primary, ten Hacken, Elisa, primary, Gao, Hui, primary, Shaim, Hila, primary, Van Roosbroeck, Katrien, primary, Calin, George, primary, O'Brien, Susan, primary, Faderl, Stefan, primary, Wang, Xuemei, primary, Wierda, William G., primary, Rezvani, Katayoun, primary, Reuben, James M., primary, Burger, Jan A., primary, Keating, Michael J., primary, and Ferrajoli, Alessandra, primary

Published
2023
Full Text
View/download PDF

6. Supplemental Figure 3 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figure 2 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

8. Supplemental Figure 4 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figures 1,2,3,4,5 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Author

Vitale, Candida, primary, Falchi, Lorenzo, primary, ten Hacken, Elisa, primary, Gao, Hui, primary, Shaim, Hila, primary, Van Roosbroeck, Katrien, primary, Calin, George, primary, O'Brien, Susan, primary, Faderl, Stefan, primary, Wang, Xuemei, primary, Wierda, William G., primary, Rezvani, Katayoun, primary, Reuben, James M., primary, Burger, Jan A., primary, Keating, Michael J., primary, and Ferrajoli, Alessandra, primary

Published
2023
Full Text
View/download PDF

10. Supplemental Figure 5 from Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, primary, Setoyama, Tetsuro, primary, Ivan, Cristina, primary, Rodriguez-Aguayo, Cristian, primary, Fuentes-Mattei, Enrique, primary, Xiao, Lianchun, primary, Vannini, Ivan, primary, Redis, Roxana S., primary, D'Abundo, Lucilla, primary, Zhang, Xinna, primary, Nicoloso, Milena S., primary, Rossi, Simona, primary, Gonzalez-Villasana, Vianey, primary, Rupaimoole, Rajesha, primary, Ferracin, Manuela, primary, Morabito, Fortunato, primary, Neri, Antonino, primary, Ruvolo, Peter P., primary, Ruvolo, Vivian R., primary, Pecot, Chad V., primary, Amadori, Dino, primary, Abruzzo, Lynne, primary, Calin, Steliana, primary, Wang, Xuemei, primary, You, M. James, primary, Ferrajoli, Alessandra, primary, Orlowski, Robert, primary, Plunkett, William, primary, Lichtenberg, Tara M., primary, Davuluri, Ramana V., primary, Berindan-Neagoe, Ioana, primary, Negrini, Massimo, primary, Wistuba, Ignacio I., primary, Kantarjian, Hagop M., primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Keating, Michael J., primary, Fabbri, Muller, primary, and Calin, George A., primary

Published
2023
Full Text
View/download PDF

13. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs

Author

Londin, Eric, Loher, Phillipe, Telonis, Aristeidis G., Quann, Kevin, Clark, Peter, Jing, Yi, Hatzimichael, Eleftheria, Kirino, Yohei, Honda, Shozo, Lally, Michelle, Ramratnam, Bharat, Comstock, Clay E. S., Knudsen, Karen E., Gomella, Leonard, Spaeth, George L., Hark, Lisa, Katz, L. Jay, Witkiewicz, Agnieszka, Rostami, Abdolmohamad, Jimenez, Sergio A., Hollingsworth, Michael A., Yeh, Jen Jen, Shaw, Chad A., McKenzie, Steven E., Bray, Paul, Nelson, Peter T., Zupo, Simona, Van Roosbroeck, Katrien, Keating, Michael J., Calin, George A., Yeo, Charles, Jimbo, Masaya, Cozzitorto, Joseph, Brody, Jonathan R., Delgrosso, Kathleen, Mattick, John S., Fortina, Paolo, and Rigoutsos, Isidore

Published
2015

18. Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19

Author

Esposito, Carla L., primary, Van Roosbroeck, Katrien, additional, Santamaria, Gianluca, additional, Rotoli, Deborah, additional, Sandomenico, Annamaria, additional, Wierda, William G., additional, Ferrajoli, Alessandra, additional, Ruvo, Menotti, additional, Calin, George A., additional, de Franciscis, Vittorio, additional, and Catuogno, Silvia, additional

Published
2021
Full Text
View/download PDF

20. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course

Author

Put, Natalie, Van Roosbroeck, Katrien, Konings, Peter, Meeus, Peter, Brusselmans, Caroline, Rack, Katrina, Gervais, Carine, Nguyen-Khac, Florence, Chapiro, Elise, Radford-Weiss, Isabelle, Struski, Stéphanie, Dastugue, Nicole, Gachard, Nathalie, Lefebvre, Christine, Barin, Carole, Eclache, Virginie, Fert-Ferrer, Sandra, Laibe, Sophy, Mozziconacci, Marie-Joëlle, Quilichini, Benoît, Poirel, Hélène A., Wlodarska, Iwona, Hagemeijer, Anne, Moreau, Yves, Vandenberghe, Peter, Michaux, Lucienne, and on behalf of the BCGHo and the GFCH

Published
2012
Full Text
View/download PDF

22. FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Author

Debackere, Koen, primary, van der Krogt, Jo-Anne, primary, Tousseyn, Thomas, primary, Ferreiro, Julio Antonio Finalet, primary, Van Roosbroeck, Katrien, primary, Marcelis, Lukas, primary, Graux, Carlos, primary, Dierickx, Daan, primary, Ameye, Geneviève, primary, Vandenberghe, Peter, primary, Michaux, Lucienne, primary, Cools, Jan, primary, and Wlodarska, Iwona, primary

Published
2020
Full Text
View/download PDF

23. The involvement of microRNA in the pathogenesis of Richter syndrome

Author

Van Roosbroeck, Katrien, primary, Bayraktar, Recep, additional, Calin, Steliana, additional, Bloehdorn, Johannes, additional, Dragomir, Mihnea Paul, additional, Okubo, Keishi, additional, Bertilaccio, Maria Teresa Sabrina, additional, Zupo, Simonetta, additional, You, M. James, additional, Gaidano, Gianluca, additional, Rossi, Davide, additional, Chen, Shih-Shih, additional, Chiorazzi, Nicholas, additional, Thompson, Philip A., additional, Ferrajoli, Alessandra, additional, Bertoni, Francesco, additional, Stilgenbauer, Stephan, additional, Keating, Michael J., additional, and Calin, George A., additional

Published
2018
Full Text
View/download PDF

24. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations

Author

Shah, Maitri Y., primary, Ferracin, Manuela, additional, Pileczki, Valentina, additional, Chen, Baoqing, additional, Redis, Roxana, additional, Fabris, Linda, additional, Zhang, Xinna, additional, Ivan, Cristina, additional, Shimizu, Masayoshi, additional, Rodriguez-Aguayo, Cristian, additional, Dragomir, Mihnea, additional, Van Roosbroeck, Katrien, additional, Almeida, Maria Ines, additional, Ciccone, Maria, additional, Nedelcu, Daniela, additional, Cortez, Maria Angelica, additional, Manshouri, Taghi, additional, Calin, Steliana, additional, Muftuoglu, Muharrem, additional, Banerjee, Pinaki P., additional, Badiwi, Mustafa H., additional, Parker-Thornburg, Jan, additional, Multani, Asha, additional, Welsh, James William, additional, Estecio, Marcos Roberto, additional, Ling, Hui, additional, Tomuleasa, Ciprian, additional, Dima, Delia, additional, Yang, Hui, additional, Alvarez, Hector, additional, You, M. James, additional, Radovich, Milan, additional, Shpall, Elizabeth, additional, Fabbri, Muller, additional, Rezvani, Katy, additional, Girnita, Leonard, additional, Berindan-Neagoe, Ioana, additional, Maitra, Anirban, additional, Verstovsek, Srdan, additional, Fodde, Riccardo, additional, Bueso-Ramos, Carlos, additional, Gagea, Mihai, additional, Manero, Guillermo Garcia, additional, and Calin, George A., additional

Published
2018
Full Text
View/download PDF

25. A miR-155/TP53 regulatory feedback loop involved in resistance to therapy in lung cancer and leukemia

Author

Van Roosbroeck, Katrien, Fanini, Francesca, Setoyama, Tetsuro, Ivan, Cristina, Rodriguez-Aguayo, Cristian, Vannini, Ivan, Redis, Roxana S., D’Abundo, Lucilla, Zhang, Xinna, Xiao, Lianchun, Nicoloso, Milena S., Rossi, Simona, Gonzalez-Villasana, Vianey, Rupaimoole, Rajesha, Ferracin, Manuela, Morabito, Fortunato, Neri, Antonino, Ruvolo, Peter P., Ruvolo, Vivian R., Pecot, Chad V., Amadori, Dino, Abruzzo, Lynne, Calin, Steliana, Wang, Xuemei, You, M. James, Ferrajoli, Alessandra, Orlowski, Robert, Plunkett, William, Davuluri, Ramana V., Berindan-Neagoe, Ioana, Negrini, Massimo, Wistuba, Ignacio I., Kantarjian, Hagop M., Sood, Anil K., Lopez-Berestein, Gabriel, Keating, Michael J., Fabbri, Muller, and Calin, George A.

Subjects
Gene Expression Regulation, Neoplastic, Mice, MicroRNAs, Lung Neoplasms, Drug Resistance, Neoplasm, Cell Line, Tumor, Animals, Antagomirs, Humans, Cisplatin, Tumor Suppressor Protein p53, Article
Published
2016

26. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies

Author

Van Roosbroeck, Katrien, Finalet Ferreiro, Julio, Tousseyn, Thomas, van der Krogt, Jo-Anne, Michaux, Lucienne, Pienkowska-Grela, Barbara, Theate, Ivan, De Paepe, Pascale, Dierickx, Daan, Doyen, Chantal, Put, Natalie, Cools, Jan, Vandenberghe, Peter, and Wlodarska, Iwona

Subjects
hemic and lymphatic diseases
Abstract

The recurrent 9p24.1 aberrations in lymphoid malignancies potentially involving four cancer-related and druggable genes (JAK2, CD274/PDL1, PDCD1LG2/PDL2, and KDM4C/JMJD2Cl) are incompletely characterized. To gain more insight into the anatomy of these abnormalities, at first we studied 9p24.1 alterations in 18 leukemia/lymphoma cases using cytogenetic and molecular techniques. The aberrations comprised structural (nine cases) and numerical (nine cases) alterations. The former lesions were heterogeneous but shared a common breakpoint region of 200 kb downstream of JAK2. The rearrangements predominantly targeted the PDL locus. We have identified five potential partner genes of PDL1/2: PHACTR4 (1p34), N4BP2 (4p14), EEF1A1 (6q13), AK2 (9p24.1), and IGL (22q11). Interestingly, the cryptic JAK2-PDL1 rearrangement was generated by a microdeletion spanning the 3'JAK2-5'PDL1 region. JAK2 was additionally involved in a cytogenetically cryptic IGH-mediated t(9;14)(p24.1;q32) found in two patients. This rare but likely underestimated rearrangement highlights the essential role of JAK2 in B-cell neoplasms. Cases with amplification of 9p24.1 were diagnosed as primary mediastinal B-cell lymphoma (five cases) and T-cell lymphoma (four cases). The smallest amplified 9p24.1 region was restricted to the JAK2-PDL1/2-RANBP6 interval. In the next step, we screened 200 cases of classical Hodgkin lymphoma by interphase FISH and identified PDL1/2 rearrangement (CIITA- and IGH-negative) in four cases (2%), what is a novel finding. Forty (25%) cases revealed high level amplification of 9p24.1, including four cases with a selective amplification of PDL1/2. Altogether, the majority of 9p24.1 rearrangements occurring in lymphoid malignancies seem to target the programmed death-1 ligands, what potentiates the therapeutic activity of PD-1 blockade in these tumors. © 2016 Wiley Periodicals, Inc. ispartof: Genes, Chromosomes & Cancer vol:55 issue:5 pages:428-441 ispartof: location:United States status: published

Published
2016

27. MicroRNAs in CLL: miRacle or miRage for prognosis and targeted therapies?

Author

Van Roosbroeck, Katrien and Calin, George A.

Subjects
Chromosome Aberrations, MicroRNAs, Drug Resistance, Neoplasm, Gene Expression Regulation, Leukemic, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Animals, Humans, Genetic Therapy, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Article
Abstract

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease and has a highly variable clinical course with survival ranging from a couple of months to several decades. MicroRNAs (miRNAs), small non-coding RNAs that regulate transcription and translation of genes, have been found to be involved in CLL initiation, progression, and resistance to therapy. In addition, they can be used as prognostic biomarkers and as targets for novel therapies. In this review, we describe the association between miRNAs and the cytogenetic aberrations commonly found in CLL, as well as with other prognostic factors. We describe the presence of miRNAs as extracellular entities in the plasma and serum of CLL patients and discuss their role in resistance to therapy. Finally, we will explore the potential of targeted miRNA therapy for the treatment of CLL, with a special emphasis on MRX34, the first miRNA mimic that is currently being evaluated for clinical use.

Published
2016

28. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

Author

Van Roosbroeck, Katrien, primary, Fanini, Francesca, additional, Setoyama, Tetsuro, additional, Ivan, Cristina, additional, Rodriguez-Aguayo, Cristian, additional, Fuentes-Mattei, Enrique, additional, Xiao, Lianchun, additional, Vannini, Ivan, additional, Redis, Roxana S., additional, D'Abundo, Lucilla, additional, Zhang, Xinna, additional, Nicoloso, Milena S., additional, Rossi, Simona, additional, Gonzalez-Villasana, Vianey, additional, Rupaimoole, Rajesha, additional, Ferracin, Manuela, additional, Morabito, Fortunato, additional, Neri, Antonino, additional, Ruvolo, Peter P., additional, Ruvolo, Vivian R., additional, Pecot, Chad V., additional, Amadori, Dino, additional, Abruzzo, Lynne, additional, Calin, Steliana, additional, Wang, Xuemei, additional, You, M. James, additional, Ferrajoli, Alessandra, additional, Orlowski, Robert, additional, Plunkett, William, additional, Lichtenberg, Tara M., additional, Davuluri, Ramana V., additional, Berindan-Neagoe, Ioana, additional, Negrini, Massimo, additional, Wistuba, Ignacio I., additional, Kantarjian, Hagop M., additional, Sood, Anil K., additional, Lopez-Berestein, Gabriel, additional, Keating, Michael J., additional, Fabbri, Muller, additional, and Calin, George A., additional

Published
2017
Full Text
View/download PDF

29. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs

Author

Jimbo, Masaya, Yeo, Charles, Katz, L. Jay, Comstock, Clay E. S., Spaeth, George L., Hark, Lisa, Mattick, John S., Rostami, Abdolmohamad, Hollingsworth, Michael A., Gomella, Leonard, Rigoutsos, Isidore, Van Roosbroeck, Katrien, Nelson, Peter T., Cozzitorto, Joseph, Shaw, Chad A., Delgrosso, Kathleen, Witkiewicz, Agnieszka, Brody, Jonathan R., Yeh, Jen Jen, Zupo, Simona, McKenzie, Steven E., Knudsen, Karen E., Fortina, Paolo, Calin, George A., Keating, Michael J., Jimenez, Sergio A., and Bray, Paul

Abstract

MicroRNAs (miRNAs) are small ∼22-nt RNAs that are important regulators of posttranscriptional gene expression. Since their initial discovery, they have been shown to be involved in many cellular processes, and their misexpression is associated with disease etiology. Currently, nearly 2,800 human miRNAs are annotated in public repositories. A key question in miRNA research is how many miRNAs are harbored by the human genome. To answer this question, we examined 1,323 short RNA sequence samples and identified 3,707 novel miRNAs, many of which are human-specific and tissue-specific. Our findings suggest that the human genome expresses a greater number of miRNAs than has previously been appreciated and that many more miRNA molecules may play key roles in disease etiology.

Published
2015
Full Text
View/download PDF

30. MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?

Author

Van Roosbroeck, Katrien and Calin, George A.

Abstract

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease and has a highly variable clinical course with survival ranging from a couple of months to several decades. MicroRNAs (miRNAs), small non-coding RNAs that regulate transcription and translation of genes, have been found to be involved in CLL initiation, progression, and resistance to therapy. In addition, they can be used as prognostic biomarkers and as targets for novel therapies. In this review, we describe the association between miRNAs and the cytogenetic aberrations commonly found in CLL, as well as with other prognostic factors. We describe the presence of miRNAs as extracellular entities in the plasma and serum of CLL patients and discuss their role in resistance to therapy. Finally, we will explore the potential of targeted miRNA therapy for the treatment of CLL, with a special emphasis on MRX34, the first miRNA mimic that is currently being evaluated for clinical use.

Published
2024
Full Text
View/download PDF

31. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, UCL - (MGD) Service d'anatomie pathologique, Van Roosbroeck, Katrien, Ferreiro, Julio Finalet, Tousseyn, Thomas, van der Krogt, Jo-Anne, Michaux, Lucienne, Pienkowska-Grela, Barbara, Théate, Ivan, De Paepe, Pascale, Dierickx, Daan, Doyen, Chantal, Put, Natalie, Cools, Jan, Vandenberghe, Peter, Wlodarska, Iwona, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, UCL - (MGD) Service d'anatomie pathologique, Van Roosbroeck, Katrien, Ferreiro, Julio Finalet, Tousseyn, Thomas, van der Krogt, Jo-Anne, Michaux, Lucienne, Pienkowska-Grela, Barbara, Théate, Ivan, De Paepe, Pascale, Dierickx, Daan, Doyen, Chantal, Put, Natalie, Cools, Jan, Vandenberghe, Peter, and Wlodarska, Iwona

Abstract

The recurrent 9p24.1 aberrations in lymphoid malignancies potentially involving four cancer-related and druggable genes (JAK2, CD274/PDL1, PDCD1LG2/PDL2, and KDM4C/JMJD2Cl) are incompletely characterized. To gain more insight into the anatomy of these abnormalities, at first we studied 9p24.1 alterations in 18 leukemia/lymphoma cases using cytogenetic and molecular techniques. The aberrations comprised structural (nine cases) and numerical (nine cases) alterations. The former lesions were heterogeneous but shared a common breakpoint region of 200 kb downstream of JAK2. The rearrangements predominantly targeted the PDL locus. We have identified five potential partner genes of PDL1/2: PHACTR4 (1p34), N4BP2 (4p14), EEF1A1 (6q13), JAK2 (9p24.1), and IGL (22q11). Interestingly, the cryptic JAK2-PDL1 rearrangement was generated by a microdeletion spanning the 3'JAK2-5'PDL1 region. JAK2 was additionally involved in a cytogenetically cryptic IGH-mediated t(9;14)(p24.1;q32) found in two patients. This rare but likely underestimated rearrangement highlights the essential role of JAK2 in B-cell neoplasms. Cases with amplification of 9p24.1 were diagnosed as primary mediastinal B-cell lymphoma (five cases) and T-cell lymphoma (four cases). The smallest amplified 9p24.1 region was restricted to the JAK2-PDL1/2-RANBP6 interval. In the next step, we screened 200 cases of classical Hodgkin lymphoma by interphase FISH and identified PDL1/2 rearrangement (CIITA- and IGH-negative) in four cases (2%), what is a novel finding. Forty (25%) cases revealed high level amplification of 9p24.1, including four cases with a selective amplification of PDL1/2. Altogether, the majority of 9p24.1 rearrangements occurring in lymphoid malignancies seem to target the programmed death-1 ligands, what potentiates the therapeutic activity of PD-1 blockade in these tumors. © 2016 Wiley Periodicals, Inc.

Published
2016

32. Allele-specific reprogramming of cancer metabolism by the long non-coding RNA CCAT2

Author

Mohamed bin Zayed Species Conservation Fund, University of Texas, Fundações de Amparo à Pesquisa (Brasil), Leukemia & Lymphoma Society (US), National Institutes of Health (US), Redis, Roxana S., Vela, Luz E., Lu, Weiqin, Ferreira de Oliveira, Juliana, Rodriguez-Aguayo, Cristian, Adamoski, Douglas, Pasculli, Barbara, Taguchi, Ayumu, Chen, Yunyun, Fernández, Agustín F., Valledor, Luis, Van Roosbroeck, Katrien, Chang, Samuel, Shah, Maitri, Kinnebrew, Garrett, Han, Leng, Atlasi, Yaser, Cheung, Lawrence H., Huang, Gilbert Y., Monroig, Paloma, Ramirez, Marc S., Catela, Ivkovic, Tina, Van, Long, Ling, Hui, Gafà, Roberta, Kapitanovic, Sanja, Lanza, Giovanni, Bankson, James A., Huang, Peng, Lai, Stephen Y., Bast, Robert C., Rosenblum, Michael G., Radovich, Milan, Ivan, Mircea, Bartholomeusz, Geoffrey, Liang, Hang, Fraga, Mario F., Widger, William R., Hanash, Samir, Berindan-Neagoe, Ioana, Lopez-Berestein, Gabriel, Ambrosio, Andre L. B., Gomes Dias, Sandra M., Calin, George A., Mohamed bin Zayed Species Conservation Fund, University of Texas, Fundações de Amparo à Pesquisa (Brasil), Leukemia & Lymphoma Society (US), National Institutes of Health (US), Redis, Roxana S., Vela, Luz E., Lu, Weiqin, Ferreira de Oliveira, Juliana, Rodriguez-Aguayo, Cristian, Adamoski, Douglas, Pasculli, Barbara, Taguchi, Ayumu, Chen, Yunyun, Fernández, Agustín F., Valledor, Luis, Van Roosbroeck, Katrien, Chang, Samuel, Shah, Maitri, Kinnebrew, Garrett, Han, Leng, Atlasi, Yaser, Cheung, Lawrence H., Huang, Gilbert Y., Monroig, Paloma, Ramirez, Marc S., Catela, Ivkovic, Tina, Van, Long, Ling, Hui, Gafà, Roberta, Kapitanovic, Sanja, Lanza, Giovanni, Bankson, James A., Huang, Peng, Lai, Stephen Y., Bast, Robert C., Rosenblum, Michael G., Radovich, Milan, Ivan, Mircea, Bartholomeusz, Geoffrey, Liang, Hang, Fraga, Mario F., Widger, William R., Hanash, Samir, Berindan-Neagoe, Ioana, Lopez-Berestein, Gabriel, Ambrosio, Andre L. B., Gomes Dias, Sandra M., and Calin, George A.

Abstract

Altered energy metabolism is a cancer hallmark as malignant cells tailor their metabolic pathways to meet their energy requirements. Glucose and glutamine are the major nutrients that fuel cellular metabolism, and the pathways utilizing these nutrients are often altered in cancer. Here, we show that the long ncRNA CCAT2, located at the 8q24 amplicon on cancer risk-associated rs6983267 SNP, regulates cancer metabolism in vitro and in vivo in an allele-specific manner by binding the Cleavage Factor I (CFIm) complex with distinct affinities for the two subunits (CFIm25 and CFIm68). The CCAT2 interaction with the CFIm complex fine-tunes the alternative splicing of Glutaminase (GLS) by selecting the poly(A) site in intron 14 of the precursor mRNA. These findings uncover a complex, allele-specific regulatory mechanism of cancer metabolism orchestrated by the two alleles of a long ncRNA.

Published
2016

34. Genomic alterations of theJAK2andPDLloci occur in a broad spectrum of lymphoid malignancies

Author

Van Roosbroeck, Katrien, primary, Ferreiro, Julio Finalet, additional, Tousseyn, Thomas, additional, van der Krogt, Jo-Anne, additional, Michaux, Lucienne, additional, Pienkowska-Grela, Barbara, additional, Theate, Ivan, additional, De Paepe, Pascale, additional, Dierickx, Daan, additional, Doyen, Chantal, additional, Put, Natalie, additional, Cools, Jan, additional, Vandenberghe, Peter, additional, and Wlodarska, Iwona, additional

Published
2016
Full Text
View/download PDF

35. Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2

Author

Redis, Roxana S., primary, Vela, Luz E., additional, Lu, Weiqin, additional, Ferreira de Oliveira, Juliana, additional, Ivan, Cristina, additional, Rodriguez-Aguayo, Cristian, additional, Adamoski, Douglas, additional, Pasculli, Barbara, additional, Taguchi, Ayumu, additional, Chen, Yunyun, additional, Fernandez, Agustin F., additional, Valledor, Luis, additional, Van Roosbroeck, Katrien, additional, Chang, Samuel, additional, Shah, Maitri, additional, Kinnebrew, Garrett, additional, Han, Leng, additional, Atlasi, Yaser, additional, Cheung, Lawrence H., additional, Huang, Gilbert Y., additional, Monroig, Paloma, additional, Ramirez, Marc S., additional, Catela Ivkovic, Tina, additional, Van, Long, additional, Ling, Hui, additional, Gafà, Roberta, additional, Kapitanovic, Sanja, additional, Lanza, Giovanni, additional, Bankson, James A., additional, Huang, Peng, additional, Lai, Stephen Y., additional, Bast, Robert C., additional, Rosenblum, Michael G., additional, Radovich, Milan, additional, Ivan, Mircea, additional, Bartholomeusz, Geoffrey, additional, Liang, Han, additional, Fraga, Mario F., additional, Widger, William R., additional, Hanash, Samir, additional, Berindan-Neagoe, Ioana, additional, Lopez-Berestein, Gabriel, additional, Ambrosio, Andre L.B., additional, Gomes Dias, Sandra M., additional, and Calin, George A., additional

Published
2016
Full Text
View/download PDF

36. Correlation Between Clinical Responses and Immune Characteristics in Patients with Relapsed CLL Treated with Ofatumumab and Lenalidomide

Author

Vitale, Candida, primary, Falchi, Lorenzo, additional, ten Hacken, Elisa, additional, Gao, Hui, additional, Shaim, Hila, additional, Van Roosbroeck, Katrien, additional, Calin, George, additional, O'Brien, Susan, additional, Faderl, Stefan, additional, Wang, Xuemei, additional, Wierda, William, additional, Rezvani, Katayoun, additional, Reuben, James M, additional, Burger, Jan A., additional, Keating, Michael, additional, and Ferrajoli, Alessandra, additional

Published
2015
Full Text
View/download PDF

37. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics.

Author

Bayraktar, Recep and Van Roosbroeck, Katrien

Abstract

Small non-coding microRNAs (miRNAs) are instrumental in physiological processes, such as proliferation, cell cycle, apoptosis, and differentiation, processes which are often disrupted in diseases like cancer. miR-155 is one of the best conserved and multifunctional miRNAs, which is mainly characterized by overexpression in multiple diseases including malignant tumors. Altered expression of miR-155 is found to be associated with various physiological and pathological processes, including hematopoietic lineage differentiation, immune response, inflammation, and tumorigenesis. Furthermore, miR-155 drives therapy resistance mechanisms in various tumor types. Therefore, miR-155-mediated signaling pathways became a potential target for the molecular treatment of cancer. In this review, we summarize the current findings of miR-155 in hematopoietic lineage differentiation, the immune response, inflammation, and cancer therapy resistance. Furthermore, we discuss the potential of miR-155-based therapeutic approaches for the treatment of cancer. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

40. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2induce myeloid malignancies via unique SNP-specific RNA mutations

Author

Shah, Maitri Y., Ferracin, Manuela, Pileczki, Valentina, Chen, Baoqing, Redis, Roxana, Fabris, Linda, Zhang, Xinna, Ivan, Cristina, Shimizu, Masayoshi, Rodriguez-Aguayo, Cristian, Dragomir, Mihnea, Van Roosbroeck, Katrien, Almeida, Maria Ines, Ciccone, Maria, Nedelcu, Daniela, Cortez, Maria Angelica, Manshouri, Taghi, Calin, Steliana, Muftuoglu, Muharrem, Banerjee, Pinaki P., Badiwi, Mustafa H., Parker-Thornburg, Jan, Multani, Asha, Welsh, James William, Estecio, Marcos Roberto, Ling, Hui, Tomuleasa, Ciprian, Dima, Delia, Yang, Hui, Alvarez, Hector, You, M. James, Radovich, Milan, Shpall, Elizabeth, Fabbri, Muller, Rezvani, Katy, Girnita, Leonard, Berindan-Neagoe, Ioana, Maitra, Anirban, Verstovsek, Srdan, Fodde, Riccardo, Bueso-Ramos, Carlos, Gagea, Mihai, Manero, Guillermo Garcia, and Calin, George A.

Abstract

The cancer-risk-associated rs6983267 single nucleotide polymorphism (SNP) and the accompanying long noncoding RNA CCAT2in the highly amplified 8q24.21 region have been implicated in cancer predisposition, although causality has not been established. Here, using allele-specific CCAT2transgenic mice, we demonstrate that CCAT2overexpression leads to spontaneous myeloid malignancies. We further identified that CCAT2is overexpressed in bone marrow and peripheral blood of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) patients. CCAT2induces global deregulation of gene expression by down-regulating EZH2 in vitro and in vivo in an allele-specific manner. We also identified a novel non-APOBEC, non-ADAR, RNA editing at the SNP locus in MDS/MPN patients and CCAT2-transgenic mice. The RNA transcribed from the SNP locus in malignant hematopoietic cells have different allelic composition from the corresponding genomic DNA, a phenomenon rarely observed in normal cells. Our findings provide fundamental insights into the functional role of rs6983267 SNP and CCAT2in myeloid malignancies.

Published
2018
Full Text
View/download PDF

41. Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course

Author

UCL - SSS/DDUV - Institut de Duve, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre de génétique médicale UCL, Put, Natalie, Van Roosbroeck, Katrien, Konings, Peter, Meeus, Peter, Brusselmans, Caroline, Rack, Katrina, Gervais, Carine, Nguyen-Khac, Florence, Chapiro, Elise, Radford-Weiss, Isabelle, Struski, Stéphanie, Dastugue, Nicole, Gachard, Nathalie, Lefebvre, Christine, Barin, Carole, Eclache, Virginie, Fert-Ferrer, Sandra, Laibe, Sophy, Mozziconacci, Marie-Joëlle, Quilichini, Benoît, Poirel, Hélène, Wlodarska, Iwona, Hagemeijer, Anne, Moreau, Yves, Vandenberghe, Peter, Michaux, Lucienne, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre de génétique médicale UCL, Put, Natalie, Van Roosbroeck, Katrien, Konings, Peter, Meeus, Peter, Brusselmans, Caroline, Rack, Katrina, Gervais, Carine, Nguyen-Khac, Florence, Chapiro, Elise, Radford-Weiss, Isabelle, Struski, Stéphanie, Dastugue, Nicole, Gachard, Nathalie, Lefebvre, Christine, Barin, Carole, Eclache, Virginie, Fert-Ferrer, Sandra, Laibe, Sophy, Mozziconacci, Marie-Joëlle, Quilichini, Benoît, Poirel, Hélène, Wlodarska, Iwona, Hagemeijer, Anne, Moreau, Yves, Vandenberghe, Peter, and Michaux, Lucienne

Abstract

Translocations involving MYC are rare in chronic lymphocytic leukemia (CLL), and up to now, their prognostic significance remains unclear. We report the characteristics of 21 patients with CLL and nine patients with prolymphocytic leukemia (PLL), diagnosed in multiple centers (n = 13), which showed an MYC translocation demonstrated by fluorescence in situ hybridization. The prevalence was estimated to be <1%. Advanced age and male predominance were observed. Morphological analysis frequently revealed the presence of prolymphocytes. A typical "CLL-immunophenotype" was found in four of nine cases with PLL. Moreover, CD5 and CD23 were frequently expressed in PLL. The latter findings are atypical for PLL and may suggest transformation or progression of an underlying CLL. MYC translocations were frequently observed with concomitant adverse cytogenetic markers, such as del(11q) (n = 8/30) and/or del(17p)/monosomy 17 (n = 7/30). In addition, the presence of unbalanced translocations (n = 24 in 13/30 cases) and complex karyotype (n = 16/30) were frequent in cases with MYC translocations. Altogether, del(17p)/monosomy 17, del(11q), and/or complex karyotype were observed in 22 of 30 patients. Survival outcome was poor: the median time to treatment was only 5 months, and overall survival (OS) from clinical diagnosis and from genetic detection was 71 and 19 months, respectively. In conclusion, CLL/PLL with MYC translocations is a rare entity, which seems to be associated with adverse prognostic features and unfavorable outcome.

Published
2012

42. JAK2 Rearrangements, Including the Novel SEC31A-JAK2 Fusion, Are Recurrent in Classical Hodgkin Lymphoma

Author

UCL - Autre, Van Roosbroeck, Katrien, Cox, Luk, Lahortiga, Idoya, Gielen, Olga, Tousseyn, Thomas, Cauwelier, Barbara, De Paepe, Pascale, Vandenberghe, Peter, Marynen, Peter, De Wolf-Peeters, Chris, Cools, Jan, Wlodarska, Iwona, 51st Annual Meeting of the American-Society-of-Hematology, UCL - Autre, Van Roosbroeck, Katrien, Cox, Luk, Lahortiga, Idoya, Gielen, Olga, Tousseyn, Thomas, Cauwelier, Barbara, De Paepe, Pascale, Vandenberghe, Peter, Marynen, Peter, De Wolf-Peeters, Chris, Cools, Jan, Wlodarska, Iwona, and 51st Annual Meeting of the American-Society-of-Hematology

Published
2009

45. Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer

Author

Hudson, Robert S, primary, Yi, Ming, additional, Volfovsky, Natalia, additional, Prueitt, Robyn L, additional, Esposito, Dominic, additional, Volinia, Stefano, additional, Liu, Chang-Gong, additional, Schetter, Aaron J, additional, Van Roosbroeck, Katrien, additional, Stephens, Robert M, additional, Calin, George A, additional, Croce, Carlo M, additional, and Ambs, Stefan, additional

Published
2013
Full Text
View/download PDF

46. Array-CGH analysis of T-ALL patients and cell lines.

Author

UCL - Autre, Lahortiga, Idoya, Graux, Carlos, Mentens, Nicole, Van Roosbroeck, Katrien, De Keersmaecker, Kim, Lambert, Frederic, Vandenberghe, Peter, Wlodarska, Iwona, Froyen, Guy, Odero, Maria D., Marynen, Peter, Cools, Jan, UCL - Autre, Lahortiga, Idoya, Graux, Carlos, Mentens, Nicole, Van Roosbroeck, Katrien, De Keersmaecker, Kim, Lambert, Frederic, Vandenberghe, Peter, Wlodarska, Iwona, Froyen, Guy, Odero, Maria D., Marynen, Peter, and Cools, Jan

Published
2006

47. JAK2, As Well As PDL1 and PDL2, are Recurrently Targeted by 9p24 Structural and Numerical Aberrations in Lymphoid Neoplasms of Both B- and T-Cell Origin

Author

Van Roosbroeck, Katrien, primary, Tousseyn, Thomas, additional, Ferreiro, Julio Finalet, additional, Lahortiga, Idoya, additional, Michaux, Lucienne, additional, Cauwelier, Barbara, additional, Pienkowska-Grela, Barbara, additional, Verhoef, Gregor, additional, Doyen, Chantal, additional, Theate, Ivan, additional, De Wolf-Peeters, Christiane, additional, Vandenberghe, Peter, additional, and Wlodarska, Iwona, additional

Published
2011
Full Text
View/download PDF

48. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia

Author

Kleppe, Maria, primary, Lahortiga, Idoya, additional, El Chaar, Tiama, additional, De Keersmaecker, Kim, additional, Mentens, Nicole, additional, Graux, Carlos, additional, Van Roosbroeck, Katrien, additional, Ferrando, Adolfo A, additional, Langerak, Anton W, additional, Meijerink, Jules P P, additional, Sigaux, François, additional, Haferlach, Torsten, additional, Wlodarska, Iwona, additional, Vandenberghe, Peter, additional, Soulier, Jean, additional, and Cools, Jan, additional

Published
2010
Full Text
View/download PDF

49. JAK2 Rearrangements, Including the Novel SEC31A-JAK2 Fusion, Are Recurrent in Classical Hodgkin Lymphoma.

Author

Van Roosbroeck, Katrien, primary, Cox, Luk, additional, Lahortiga, Idoya, additional, Gielen, Olga, additional, Tousseyn, Thomas, additional, Cauwelier, Barbara, additional, De Paepe, Pascale, additional, Vandenberghe, Peter, additional, Marynen, Peter, additional, De Wolf-Peeters, Chris, additional, Cools, Jan, additional, and Wlodarska, Iwona, additional

Published
2009
Full Text
View/download PDF

50. Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.

Author

Kleppe, Maria, primary, Lahortiga, Idoya, additional, El Chaar, Tiama, additional, De Keersmaecker, Kim, additional, Mentens, Nicole, additional, Graux, Carlos, additional, Van Roosbroeck, Katrien, additional, Ferrando, Adolfo A., additional, Langerak, Anton W, additional, Meijerink, Jules P.P., additional, Sigaux, Francois, additional, Haferlach, Torsten, additional, Wlodarska, Iwona, additional, Vandenberghe, Peter, additional, Soulier, Jean, additional, and Cools, Jan, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results